xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05997563</url>
    </required_header>
    <id_info>
      <org_study_id>681/2023</org_study_id>
      <nct_id>NCT05997563</nct_id>
    </id_info>
    <brief_title>Adjunctive Vaginal Progesterone in Management of Preterm Labor</brief_title>
    <official_title>Adjunctive Vaginal Progesterone (Micronized Progesterone Effervescent Vaginal Tablet) in Management of Preterm Labor: A Randomized Controlled Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Chulalongkorn University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Chulalongkorn University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study evaluates the addition of vaginal micronized progesterone effervescent to standard&#xD;
        treatment in the treatment of preterm labor. Half of participants will receive vaginal&#xD;
        micronized progesterone effervescent and standard treatment, while the other half will&#xD;
        receive only standard treatment.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">August 16, 2023</start_date>
    <completion_date type="Anticipated">October 31, 2025</completion_date>
    <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
    <phase>Phase 4</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>latency period</measure>
      <time_frame>13 weeks</time_frame>
      <description>time from preterm labor to delivery</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>gestational age at delivery</measure>
      <time_frame>13 weeks</time_frame>
      <description>mean gestational age at delivery</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>preterm delivery less than 34 weeks</measure>
      <time_frame>10 weeks</time_frame>
      <description>percentage of preterm delivery less than 34 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>preterm delivery less than 37 weeks</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of preterm delivery less than 37 weeks</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>neonatal complications</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of newborn with RDS, IVH, NEC, death</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>side effects</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of side effects such as headache, nausea/vomiting</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>compliance</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of complete drug use</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>good satisfaction</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of good satisfaction</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>good quality of life</measure>
      <time_frame>13 weeks</time_frame>
      <description>percentage of good quality of life</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time to the recurrence of uterine contractions</measure>
      <time_frame>13 weeks</time_frame>
      <description>mean time to the recurrence of uterine contractions</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">48</enrollment>
    <condition>Preterm Labor</condition>
    <arm_group>
      <arm_group_label>Micronized progesterone</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>Control</arm_group_label>
      <arm_group_type>No Intervention</arm_group_type>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Micronized progesterone</intervention_name>
      <description>Vaginal micronized progesterone effervescent once daily until delivery</description>
      <arm_group_label>Micronized progesterone</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  singleton pregnancy with gestational age 24-33 weeks 6 days&#xD;
  &#xD;
            -  preterm labor&#xD;
  &#xD;
            -  received treatment with tocolysis and corticosteroids&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  conditions that need immediate delivery such as fetal distress, chorioamnionitis&#xD;
  &#xD;
            -  have medical complications such as heart disease, seizure&#xD;
  &#xD;
            -  fetal anomalies&#xD;
  &#xD;
            -  cervical dilatation more than 5 cm&#xD;
  &#xD;
            -  allergy to progesterone&#xD;
  &#xD;
            -  contraindication to progesterone&#xD;
  &#xD;
            -  contraindication to tocolytic use&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <gender_based>Yes</gender_based>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>45 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Vorapong Phupong, M.D.</last_name>
      <role>Study Director</role>
      <affiliation>Chulalongkorn University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Vorapong Phupong, M.D.</last_name>
      <phone>+66816339296</phone>
      <email>vorapong.p@chula.ac.th</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Jirapat Chanratchakool, M.D.</last_name>
      <phone>+66819322352</phone>
      <email>sunnjc.jc@gmail.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Vorapong Phupong</name>
        <address>
          <city>Bangkok</city>
          <zip>10330</zip>
          <country>Thailand</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Vorapong Phupong, MD</last_name>
        <phone>+66816339296</phone>
        <email>vorapong.p@chula.ac.th</email>
      </contact>
      <contact_backup>
        <last_name>Jirapat Chanratchakool, MD</last_name>
        <email>sunnjc.jc@gmail.com</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>Thailand</country>
    </location_countries>
    <reference>
      <citation>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016 Oct;128(4):e155-64. doi: 10.1097/AOG.0000000000001711.</citation>
      <PMID>27661654</PMID>
    </reference>
    <reference>
      <citation>Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Atik RB, Bloemenkamp KW, Brady R, Briley A, Cavallaro R, Cheong YC, Chu J, Eapen A, Essex H, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Parrott S, Ross JA, Sharpe L, Stewart J, Trepel D, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016 May;20(41):1-92. doi: 10.3310/hta20410.</citation>
      <PMID>27225013</PMID>
    </reference>
    <reference>
      <citation>Facchinetti F, Vergani P, Di Tommaso M, Marozio L, Acaia B, Vicini R, Pignatti L, Locatelli A, Spitaleri M, Benedetto C, Zaina B, D'Amico R. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial. Obstet Gynecol. 2017 Jul;130(1):64-70. doi: 10.1097/AOG.0000000000002065.</citation>
      <PMID>28594783</PMID>
    </reference>
    <reference>
      <citation>Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, Williams H, Eapen AK, Roberts T, Ogwulu CC, Goranitis I, Daniels JP, Ahmed A, Bender-Atik R, Bhatia K, Bottomley C, Brewin J, Choudhary M, Crosfill F, Deb S, Duncan WC, Ewer A, Hinshaw K, Holland T, Izzat F, Johns J, Kriedt K, Lumsden MA, Manda P, Norman JE, Nunes N, Overton CE, Quenby S, Rao S, Ross J, Shahid A, Underwood M, Vaithilingam N, Watkins L, Wykes C, Horne A, Jurkovic D. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. N Engl J Med. 2019 May 9;380(19):1815-1824. doi: 10.1056/NEJMoa1813730.</citation>
      <PMID>31067371</PMID>
    </reference>
    <reference>
      <citation>Piette PCM. The pharmacodynamics and safety of progesterone. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:13-29. doi: 10.1016/j.bpobgyn.2020.06.002. Epub 2020 Jun 25.</citation>
      <PMID>32739288</PMID>
    </reference>
    <reference>
      <citation>ACOG Practice Bulletin No.142: Cerclage for the management of cervical insufficiency. Obstet Gynecol. 2014 Feb;123(2 Pt 1):372-379. doi: 10.1097/01.AOG.0000443276.68274.cc.</citation>
      <PMID>24451674</PMID>
    </reference>
    <reference>
      <citation>Cicinelli E, De Ziegler D, Morgese S, Bulletti C, Luisi D, Schonauer LM. &quot;First uterine pass effect&quot; is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril. 2004 May;81(5):1414-6. doi: 10.1016/j.fertnstert.2003.12.016.</citation>
      <PMID>15136116</PMID>
    </reference>
    <reference>
      <citation>Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007 Jan;87(1):83-7. doi: 10.1016/j.fertnstert.2006.05.067. Epub 2006 Nov 1. Erratum In: Fertil Steril. 2007 Jul;88(1):254.</citation>
      <PMID>17081536</PMID>
    </reference>
    <reference>
      <citation>Shiba R, Kinutani M, Okano S, Kawano R, Kikkawa Y. Efficacy of four vaginal progesterones for luteal phase support in frozen-thawed embryo transfer cycles: A randomized clinical trial. Reprod Med Biol. 2019 Sep 16;19(1):42-49. doi: 10.1002/rmb2.12300. eCollection 2020 Jan.</citation>
      <PMID>31956284</PMID>
    </reference>
    <reference>
      <citation>Schumacher M, Liere P, Ghoumari A. Progesterone and fetal-neonatal neuroprotection. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:50-61. doi: 10.1016/j.bpobgyn.2020.09.001. Epub 2020 Sep 8.</citation>
      <PMID>33039311</PMID>
    </reference>
    <results_reference>
      <citation>Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J; OPPTIMUM study group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016 May 21;387(10033):2106-2116. doi: 10.1016/S0140-6736(16)00350-0. Epub 2016 Feb 24. Erratum In: Lancet. 2019 Jan 19;393(10168):228. Lancet. 2019 Apr 20;393(10181):1596.</citation>
      <PMID>26921136</PMID>
    </results_reference>
    <results_reference>
      <citation>Martinez de Tejada B, Karolinski A. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015 Sep;213(3):438-9. doi: 10.1016/j.ajog.2015.05.037. Epub 2015 May 21. No abstract available.</citation>
      <PMID>26003056</PMID>
    </results_reference>
    <results_reference>
      <citation>Ashoush S, El-Kady O, Al-Hawwary G, Othman A. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand. 2017 Dec;96(12):1460-1466. doi: 10.1111/aogs.13236. Epub 2017 Oct 19.</citation>
      <PMID>28949010</PMID>
    </results_reference>
    <results_reference>
      <citation>Hyett J, Asadi N, Zare Khafri M, Vafaei H, Kasraeian M, Salehi A, Saadati N, Bazrafshan K. The use of vaginal progesterone as a maintenance therapy in women with arrested preterm labor: a double-blind placebo-randomized controlled trial. J Matern Fetal Neonatal Med. 2022 Mar;35(6):1134-1140. doi: 10.1080/14767058.2020.1743662. Epub 2020 Mar 26.</citation>
      <PMID>32216490</PMID>
    </results_reference>
    <results_reference>
      <citation>Palacio M, Ronzoni S, Sanchez-Ramos L, Murphy KE. Progestogens as Maintenance Treatment in Arrested Preterm Labor: A Systematic Review and Meta-analysis. Obstet Gynecol. 2016 Nov;128(5):989-1000. doi: 10.1097/AOG.0000000000001676.</citation>
      <PMID>27741193</PMID>
    </results_reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 8, 2023</study_first_submitted>
    <study_first_submitted_qc>August 15, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 18, 2023</study_first_posted>
    <last_update_submitted>August 28, 2023</last_update_submitted>
    <last_update_submitted_qc>August 28, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 30, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
      <investigator_full_name>Vorapong Phupong</investigator_full_name>
      <investigator_title>Professor Vorapong Phupong</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Premature Birth</mesh_term>
      <mesh_term>Obstetric Labor, Premature</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Progesterone</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05997563
  org study id: 681/2023
  nct id: NCT05997563
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This study evaluates the addition of vaginal micronized progesterone effervescent to standard
        treatment in the treatment of preterm labor. Half of participants will receive vaginal
        micronized progesterone effervescent and standard treatment, while the other half will
        receive only standard treatment.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: latency period
  time frame: 13 weeks
  description: time from preterm labor to delivery
  measure: gestational age at delivery
  time frame: 13 weeks
  description: mean gestational age at delivery
  measure: preterm delivery less than 34 weeks
  time frame: 10 weeks
  description: percentage of preterm delivery less than 34 weeks
  measure: preterm delivery less than 37 weeks
  time frame: 13 weeks
  description: percentage of preterm delivery less than 37 weeks
  measure: neonatal complications
  time frame: 13 weeks
  description: percentage of newborn with RDS, IVH, NEC, death
  measure: side effects
  time frame: 13 weeks
  description: percentage of side effects such as headache, nausea/vomiting
  measure: compliance
  time frame: 13 weeks
  description: percentage of complete drug use
  measure: good satisfaction
  time frame: 13 weeks
  description: percentage of good satisfaction
  measure: good quality of life
  time frame: 13 weeks
  description: percentage of good quality of life
  measure: Time to the recurrence of uterine contractions
  time frame: 13 weeks
  description: mean time to the recurrence of uterine contractions
  arm group label: Micronized progesterone
  arm group type: Active Comparator
  arm group label: Control
  arm group type: No Intervention
  intervention type: Drug
  intervention name: Micronized progesterone
  description: Vaginal micronized progesterone effervescent once daily until delivery
  arm group label: Micronized progesterone
  criteria: 
  gender: Female
  gender based: Yes
  minimum age: 18 Years
  maximum age: 45 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Vorapong Phupong, M.D.
  role: Study Director
  affiliation: Chulalongkorn University
  last name: Vorapong Phupong, M.D.
  phone: +66816339296
  email: vorapong.p@chula.ac.th
  last name: Jirapat Chanratchakool, M.D.
  phone: +66819322352
  email: sunnjc.jc@gmail.com
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  country: Thailand
  citation: American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016 Oct;128(4):e155-64. doi: 10.1097/AOG.0000000000001711.
  PMID: 27661654
  citation: Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Atik RB, Bloemenkamp KW, Brady R, Briley A, Cavallaro R, Cheong YC, Chu J, Eapen A, Essex H, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Parrott S, Ross JA, Sharpe L, Stewart J, Trepel D, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016 May;20(41):1-92. doi: 10.3310/hta20410.
  PMID: 27225013
  citation: Facchinetti F, Vergani P, Di Tommaso M, Marozio L, Acaia B, Vicini R, Pignatti L, Locatelli A, Spitaleri M, Benedetto C, Zaina B, D'Amico R. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial. Obstet Gynecol. 2017 Jul;130(1):64-70. doi: 10.1097/AOG.0000000000002065.
  PMID: 28594783
  citation: Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, Williams H, Eapen AK, Roberts T, Ogwulu CC, Goranitis I, Daniels JP, Ahmed A, Bender-Atik R, Bhatia K, Bottomley C, Brewin J, Choudhary M, Crosfill F, Deb S, Duncan WC, Ewer A, Hinshaw K, Holland T, Izzat F, Johns J, Kriedt K, Lumsden MA, Manda P, Norman JE, Nunes N, Overton CE, Quenby S, Rao S, Ross J, Shahid A, Underwood M, Vaithilingam N, Watkins L, Wykes C, Horne A, Jurkovic D. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. N Engl J Med. 2019 May 9;380(19):1815-1824. doi: 10.1056/NEJMoa1813730.
  PMID: 31067371
  citation: Piette PCM. The pharmacodynamics and safety of progesterone. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:13-29. doi: 10.1016/j.bpobgyn.2020.06.002. Epub 2020 Jun 25.
  PMID: 32739288
  citation: ACOG Practice Bulletin No.142: Cerclage for the management of cervical insufficiency. Obstet Gynecol. 2014 Feb;123(2 Pt 1):372-379. doi: 10.1097/01.AOG.0000443276.68274.cc.
  PMID: 24451674
  citation: Cicinelli E, De Ziegler D, Morgese S, Bulletti C, Luisi D, Schonauer LM. "First uterine pass effect" is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril. 2004 May;81(5):1414-6. doi: 10.1016/j.fertnstert.2003.12.016.
  PMID: 15136116
  citation: Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007 Jan;87(1):83-7. doi: 10.1016/j.fertnstert.2006.05.067. Epub 2006 Nov 1. Erratum In: Fertil Steril. 2007 Jul;88(1):254.
  PMID: 17081536
  citation: Shiba R, Kinutani M, Okano S, Kawano R, Kikkawa Y. Efficacy of four vaginal progesterones for luteal phase support in frozen-thawed embryo transfer cycles: A randomized clinical trial. Reprod Med Biol. 2019 Sep 16;19(1):42-49. doi: 10.1002/rmb2.12300. eCollection 2020 Jan.
  PMID: 31956284
  citation: Schumacher M, Liere P, Ghoumari A. Progesterone and fetal-neonatal neuroprotection. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:50-61. doi: 10.1016/j.bpobgyn.2020.09.001. Epub 2020 Sep 8.
  PMID: 33039311
  citation: Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J; OPPTIMUM study group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016 May 21;387(10033):2106-2116. doi: 10.1016/S0140-6736(16)00350-0. Epub 2016 Feb 24. Erratum In: Lancet. 2019 Jan 19;393(10168):228. Lancet. 2019 Apr 20;393(10181):1596.
  PMID: 26921136
  citation: Martinez de Tejada B, Karolinski A. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015 Sep;213(3):438-9. doi: 10.1016/j.ajog.2015.05.037. Epub 2015 May 21. No abstract available.
  PMID: 26003056
  citation: Ashoush S, El-Kady O, Al-Hawwary G, Othman A. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand. 2017 Dec;96(12):1460-1466. doi: 10.1111/aogs.13236. Epub 2017 Oct 19.
  PMID: 28949010
  citation: Hyett J, Asadi N, Zare Khafri M, Vafaei H, Kasraeian M, Salehi A, Saadati N, Bazrafshan K. The use of vaginal progesterone as a maintenance therapy in women with arrested preterm labor: a double-blind placebo-randomized controlled trial. J Matern Fetal Neonatal Med. 2022 Mar;35(6):1134-1140. doi: 10.1080/14767058.2020.1743662. Epub 2020 Mar 26.
  PMID: 32216490
  citation: Palacio M, Ronzoni S, Sanchez-Ramos L, Murphy KE. Progestogens as Maintenance Treatment in Arrested Preterm Labor: A Systematic Review and Meta-analysis. Obstet Gynecol. 2016 Nov;128(5):989-1000. doi: 10.1097/AOG.0000000000001676.
  PMID: 27741193
  responsible party type: Principal Investigator
  investigator affiliation: Chulalongkorn University
  investigator full name: Vorapong Phupong
  investigator title: Professor Vorapong Phupong
  mesh term: Premature Birth
  mesh term: Obstetric Labor, Premature
  mesh term: Progesterone
  sharing ipd: Undecided